カテゴリー： 世界, 医療/バイオ, Grand View Research

世界のアンチセンス・RNAi治療薬市場2023-2030：技術別、用途別、投与経路別、地域別

【英語タイトル】Antisense & RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology, By Application, By Route Of Administration, By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23NOV001）・商品コード：GRV23NOV001
・発行会社（調査会社）：Grand View Research
・発行日：2023年9月
・ページ数：160
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

アンチセンス・RNAi治療薬市場の成長と動向
Grand View Research, Inc.の最新レポートによると、アンチセンス・RNAi治療薬の世界市場規模は、2023年から2030年にかけて年平均成長率18.06％で拡大し、2030年には142.5億米ドルに達する見込みです。生物学的ベクターやナノテクノロジーの開発、新規薬剤分子の上市を含む臨床研究に対する資金援助の増加は、製品開発において重要であり、市場拡大の原動力となっています。

多国籍医療機関は、さまざまな疾患に対する認識を高め、新規治療法の開発を支援しています。民間研究機関や企業が、研究機関を支援する形で臨床試験の実施に参画していることも、この分野の拡大を大きく後押しすると予測されます。例えば、2022年3月、Biogen Inc.とIonis Pharmaceuticals, Inc.は、筋萎縮性側索硬化症（ALS）患者を治療するための治験用アンチセンス・オリゴヌクレオチドの第1相試験の結果を発表しました。業界関係者によるこのような臨床試験の増加は、アンチセンスおよびRNAi療法に基づく製品の発売を増加させることにより、市場の成長を促進すると予想されます。

アンチセンス療法やRNAi療法は、細胞の成長サイクルに影響を与え、核酸を標的とする様々な疾患の治療に使用することができます。遺伝子発現を再生し、タンパク質産生を制御するmiRNAの能力は、結果的に産業の進歩に影響を与え、大きな注目を集めています。米国科学振興協会（American Association for the Advancement of Science）が2023年7月に発表した論文によると、米国マサチューセッツ工科大学（UMass Chan Medical School）とラッシュ大学メディカルセンター（RUSH University Medical Center）が開発したアンチセンス療法が、脆弱X症候群（fragile X syndrome）の患者から採取した細胞標本でFMRPというタンパク質の産生を回復させるのに有用であることが判明したとのことです。業界におけるこのような進歩は、予測期間中、多くの疾患を治療するためのRNAiおよびアンチセンス治療薬の需要を促進すると予想されます。

アンチセンス・RNAi治療薬市場レポートハイライト

- アンチセンスRNA技術は、神経変性疾患や遺伝性疾患などの疾患への幅広い応用により、技術分野で2022年に最大の収益シェアを占めました。

- RNA干渉分野は技術分野で最速の成長が見込まれます。この技術はさらにsiRNAとmiRNAに区分されます。miRNAは細胞の同一性の維持に重要な役割を果たすため、癌の広がりをよりよく理解するために採用されています。

- 用途別では、遺伝病分野が38.9%の収益シェアで市場を独占しました。このセグメントの優位性は、主要企業が新規遺伝病治療法の開発にますます注力していることに起因しています。

- 投与経路別では、髄腔内注射が2022年の売上高で44.6%のシェアを占めました。脊髄麻酔、化学療法、疼痛管理に広く使用されていることが、このセグメントの優位性の原因です。

- アンチセンスおよびRNAi治療薬の世界市場で最大の売上シェアを占めたのは北米でした。同地域の優位性は、同地域に複数のプレーヤーが存在し、業界における地位を強化しようと努力していることに起因しています。

- 欧州は、Secarna社のような主要企業が同地域で事業を展開し、拡大していることから、2023年から2030年までの予測期間で最も速い成長を記録すると予測されています。

第1章 調査方法・範囲
第2章 エグゼクティブサマリー
第3章 市場変数・傾向・範囲
第4章 世界のアンチセンス・RNAi治療薬市場：技術別ビジネス分析
第5章 世界のアンチセンス・RNAi治療薬市場：用途別ビジネス分析
第6章 世界のアンチセンス・RNAi治療薬市場：投与経路別ビジネス分析
第7章 世界のアンチセンス・RNAi治療薬市場：地域別ビジネス分析
第8章 競争状況

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Market Definitions
1.2. Regional Scope
1.3. Estimates & Forecasts Timeline
1.4. Objectives
1.4.1. Objective 1
1.4.2. Objective 2
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased database
1.6.2. GVR’s internal database
1.6.3. Secondary sources
1.6.4. Primary research
1.7. Information or Data Analysis
1.7.1. Data analysis models
1.8. Marker Formulation & Validation
1.9. Market Model
1.9.1. Commodity flow analysis
1.10. List of Secondary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Presence of strong pipeline product portfolio
3.2.1.2. Introduction of technological advancements in drug delivery
3.2.1.3. Implementation of favorable government initiatives & external funding for R&D exercises
3.2.1.4. Rising collaborations between pharmaceutical companies
3.2.2. Market Restraint Analysis
3.2.2.1. Expensive and tedious research programs
3.2.2.2. Delivery of RNAi therapeutics and off-target effects
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Technology Business Analysis
4.1. Antisense and RNAi Therapeutics Market: Technology Movement Analysis
4.2. RNA Interference
4.2.1. RNA Interference Market, 2018 – 2030 (USD Million)
4.3. Antisense RNA
4.3.1. Antisense RNA Market, 2018 – 2030 (USD Million)
Chapter 5. Application Business Analysis
5.1. Antisense and RNAi Therapeutics Market: Application Movement Analysis
5.2. Ocular
5.2.1. Ocular Market, 2018 – 2030 (USD Million)
5.3. Cardio metabolic & Renal Disorders
5.3.1. Cardio metabolic & Renal Disorders Market, 2018 – 2030 (USD Million)
5.4. Respiratory Disorders
5.4.1. Respiratory Disorders Market, 2018 – 2030 (USD Million)
5.5. Cancer
5.5.1. Cancer Market, 2018 – 2030 (USD Million)
5.6. Neurodegenerative Disorders
5.6.1. Neurodegenerative Disorders Market, 2018 – 2030 (USD Million)
5.7. Genetic Disorders
5.7.1. Genetic Disorders Market, 2018 – 2030 (USD Million)
5.8. Infectious Diseases
5.8.1. Infectious Diseases Market, 2018 – 2030 (USD Million)
5.9. Skin Diseases
5.9.1. Skin Diseases Market, 2018 – 2030 (USD Million)
5.10. Other
5.10.1. Other Market, 2018 – 2030 (USD Million)
Chapter 6. Route of Administration Business Analysis
6.1. Antisense and RNAi Therapeutics Market: Route of Administration Movement Analysis
6.2. Intravenous Injections
6.2.1. Intravenous Injections Market, 2018 – 2030 (USD Million)
6.3. Intrathecal Injections
6.3.1. Intrathecal Injections Market, 2018 – 2030 (USD Million)
6.4. Subcutaneous Injections
6.4.1. Subcutaneous Injections Market, 2018 – 2030 (USD Million)
6.5. Others
6.5.1. Others Market, 2018 – 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Antisense and RNAi Therapeutics Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. North America Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Target Disease Prevalence
7.2.2.3. Competitive Scenario
7.2.2.4. Regulatory Framework
7.2.2.5. U.S. Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. Canada Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3. Europe
7.3.1. Europe Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Target Disease Prevalence
7.3.2.3. Competitive Scenario
7.3.2.4. Regulatory Framework
7.3.2.5. UK Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Germany Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. France Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. Italy Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Spain Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Denmark Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Sweden Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Norway Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Competitive Scenario
7.4.2.4. Regulatory Framework
7.4.2.5. Japan Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. China Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. India Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Australia Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Thailand Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. South Korea Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Competitive Scenario
7.5.2.4. Regulatory Framework
7.5.2.5. Brazil Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Mexico Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Regulatory Framework
7.5.4.5. Argentina Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.6. MEA
7.6.1. MEA Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Competitive Scenario
7.6.2.4. Regulatory Framework
7.6.2.5. South Africa Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. Saudi Arabia Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. UAE Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. Kuwait Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2022
8.4. Company Profiles/Listing
8.4.1. Olix Pharmaceuticals
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. GSK plc.
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Sanofi Aventis / Genzyme
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Alnylam Pharmaceuticals
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Isis Pharmaceuticals/ Ionis Pharmaceuticals
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Benitec Biopharma Ltd.
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Arbutus Biopharma Ltd.
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Silence Therapeutics
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Bio-Path Holdings Inc.
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Antisense Therapeutics Limited.
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 4 Global Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 5 Global Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 6 Global Antisense and RNAi Therapeutics Market, By Region, 2018 - 2030 (USD Million)
Table 7 North America Antisense and RNAi Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 8 North America Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 9 North America Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 10 North America Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 11 U.S. Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 12 U.S. Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 13 U.S. Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 14 Canada Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 15 Canada Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 16 Canada Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 17 Europe Antisense and RNAi Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 18 Europe Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 19 Europe Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 20 Europe Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 21 UK Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 22 UK Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 23 UK Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 24 Germany Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 25 Germany Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 26 Germany Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 27 France Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 28 France Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 29 France Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 30 Spain Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 31 Spain Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 32 Spain Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 33 Italy Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 34 Italy Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 35 Italy Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 36 Denmark Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 37 Denmark Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 38 Denmark Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 39 Norway Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 40 Norway Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 41 Norway Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 42 Sweden Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 43 Sweden Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 44 Sweden Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 45 Asia Pacific Antisense and RNAi Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 47 Asia Pacific Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 48 Asia Pacific Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 49 China Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 50 China Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 51 China Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 52 Japan Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 53 Japan Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 54 Japan Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 55 India Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 56 India Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 57 India Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 58 South Korea Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 59 South Korea Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 60 South Korea Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 61 Australia Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 62 Australia Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 63 Australia Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 64 Thailand Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 65 Thailand Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 66 Thailand Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 67 Latin America Antisense and RNAi Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 68 Latin America Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 69 Latin America Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 70 Latin America Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 71 Brazil Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 72 Brazil Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 73 Brazil Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 74 Mexico Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 75 Mexico Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 76 Mexico Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 77 Argentina Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 78 Argentina Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 79 Argentina Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 80 MEA Antisense and RNAi Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 81 MEA Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 82 MEA Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 83 MEA Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 84 South Africa Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 85 South Africa Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 86 South Africa Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 87 UAE Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 88 UAE Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 89 UAE Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 90 Saudi Arabia Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 91 Saudi Arabia Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 92 Saudi Arabia Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 93 Kuwait Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 94 Kuwait Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 95 Kuwait Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Antisense and RNAi therapeutics market segmentation
Fig. 8 Market snapshot, 2022
Fig. 9 Market trends & outlook
Fig. 10 Market driver relevance analysis (current & future impact)
Fig. 11 Market restraint relevance analysis (current & future impact)
Fig. 12 PESTEL analysis
Fig. 13 Porter’s five forces analysis
Fig. 14 Global antisense and RNAi therapeutics market: Technology outlook and key takeaways
Fig. 15 Global antisense and RNAi therapeutics market: Technology movement analysis
Fig. 16 Global antisense and RNAi therapeutics market, for RNA interference, 2018 - 2030 (USD Million)
Fig. 17 Global antisense and RNAi therapeutics market, for siRNA, 2018 - 2030 (USD Million)
Fig. 18 Global antisense and RNAi therapeutics market, for miRNA, 2018 - 2030 (USD Million)
Fig. 19 Global antisense and RNAi therapeutics market, for Antisense RNA, 2018 - 2030 (USD Million)
Fig. 20 Global antisense and RNAi therapeutics market: Application outlook and key takeaways
Fig. 21 Global antisense and RNAi therapeutics market: Application movement analysis
Fig. 22 Global antisense and RNAi therapeutics market, for Ocular, 2018 - 2030 (USD Million)
Fig. 23 Global antisense and RNAi therapeutics market, for Cancer, 2018 - 2030 (USD Million)
Fig. 24 Global antisense and RNAi therapeutics market, for Cardio metabolic & Renal Disorders Diseases (CVDs), 2018 - 2030 (USD Million)
Fig. 25 Global antisense and RNAi therapeutics market, for Respiratory Disorders, 2018 - 2030 (USD Million)
Fig. 26 Global antisense and RNAi therapeutics market, for Skin Diseases, 2018 - 2030 (USD Million)
Fig. 27 Global antisense and RNAi therapeutics market, for Neurodegenerative Disorders, 2018 - 2030 (USD Million)
Fig. 28 Global antisense and RNAi therapeutics market, for Genetic Disorders, 2018 - 2030 (USD Million)
Fig. 29 Global antisense and RNAi therapeutics market, for Infectious Diseases, 2018 - 2030 (USD Million)
Fig. 30 Global antisense and RNAi therapeutics market, for Others, 2018 - 2030 (USD Million)
Fig. 31 Global antisense and RNAi therapeutics market: Route of Administration outlook and key takeaways
Fig. 32 Global antisense and RNAi therapeutics market: Route of Administration movement analysis
Fig. 33 Global antisense and RNAi therapeutics market, for Intravenous Injections, 2018 - 2030 (USD Million)
Fig. 34 Global antisense and RNAi therapeutics market, for Intrathecal Injections, 2018 - 2030 (USD Million)
Fig. 35 Global antisense and RNAi therapeutics market, for Subcutaneous Injections, 2018 - 2030 (USD Million)
Fig. 36 Global antisense and RNAi therapeutics market, for other delivery methods, 2018 - 2030 (USD Million)
Fig. 37 Regional marketplace: Key takeaways
Fig. 38 Regional outlook, 2022 & 2030
Fig. 39 Global antisense and RNAi therapeutics market: Region movement analysis
Fig. 40 North America antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 41 U.S. antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 42 Canada antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 43 Europe antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 44 Germany antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 45 UK antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 46 France antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 47 Italy antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 48 Spain antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 49 Denmark antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 50 Sweden antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 51 Norway antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 52 Asia Pacific antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 53 Japan antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 54 China antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 55 India antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 56 Australia antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 57 South Korea antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 58 Thailand antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 59 Latin America antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 60 Brazil antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 61 Mexico antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 62 Argentina antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 63 Middle East and Africa antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 64 South Africa antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 65 Saudi Arabia antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 66 UAE antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)
Fig. 67 Kuwait antisense and RNAi therapeutics market, 2018 - 2030 (USD Million)

★調査レポート[世界のアンチセンス・RNAi治療薬市場2023-2030：技術別、用途別、投与経路別、地域別] (コード：GRV23NOV001)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のアンチセンス・RNAi治療薬市場2023-2030：技術別、用途別、投与経路別、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のアンチセンス・RNAI治療薬市場2024-2030：技術別（RNA干渉、アンチセンスRNA）、用途別（眼疾患、遺伝子疾患）、投与経路別、地域別
  • 世界のアンチセンス・RNAi治療薬市場2023-2030：技術別（RNA干渉、アンチセンスRNA）、用途別（遺伝子疾患、がん、感染症、神経変性疾患、心代謝・腎疾患、眼疾患、呼吸器疾患、皮膚疾患）、投与経路別（静脈注射、髄腔内注射、皮下注射、その他送達方法）、地域別
  • 世界のピーナッツアレルギー治療市場2023-2030：薬物クラス別（抗ヒスタミン薬、エピネフリン）、投与経路別、流通チャネル別、地域別
  • 世界のピーナッツアレルギー治療薬市場2024-2030：薬剤クラス別（抗ヒスタミン薬、エピネフリン）、投与経路別、流通チャネル別、地域別
  • 世界のペプチド治療薬市場2024-2030：用途別（癌、代謝異常）、種類別（ジェネリック、革新的）、メーカー種類別、投与経路別、合成技術別、地域別
  • 世界の解毒薬市場2024-2030：種類別（化学的解毒剤、物理的解毒剤、薬理学的解毒剤）、投与経路別、流通チャネル別、エンドユーザー別、地域別
  • 世界の筋弛緩剤市場2023-2030：薬剤種類別（骨格筋弛緩剤、顔面筋弛緩剤）、投与経路別、流通チャネル別、地域別
  • 世界の降圧薬市場2024-2030：薬剤クラス別（利尿薬、ACE阻害薬）、種類別（一次、二次）、投与経路別、流通チャネル別、地域別
  • 世界のペプチド治療薬市場2023-2030：用途別、種類別（ジェネリック、革新的）、メーカー種類別、投与経路別、合成技術別、地域別
  • 世界のブランドジェネリック市場2023-2030：薬物クラス別（アルキル化剤、代謝拮抗剤、抗高血圧剤）、用途別、投与経路別、流通チャネル別、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆